245 related articles for article (PubMed ID: 28423656)
1. Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells.
Wen Y; Zhao RQ; Zhang YK; Gupta P; Fu LX; Tang AZ; Liu BM; Chen ZS; Yang DH; Liang G
Oncotarget; 2017 May; 8(18):29760-29770. PubMed ID: 28423656
[TBL] [Abstract][Full Text] [Related]
2. The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Zhou H; Fu LX; Li L; Chen YY; Zhu HQ; Zhou JL; Lv MX; Gan RZ; Zhang XX; Liang G
J Ethnopharmacol; 2020 Oct; 261():113118. PubMed ID: 32621953
[TBL] [Abstract][Full Text] [Related]
3. The epigallocatechin gallate derivative Y
Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G
J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759
[TBL] [Abstract][Full Text] [Related]
4. Epigallocatechin-3-gallate promotes apoptosis and reversal of multidrug resistance in esophageal cancer cells.
Liu L; Ju Y; Wang J; Zhou R
Pathol Res Pract; 2017 Oct; 213(10):1242-1250. PubMed ID: 28964574
[TBL] [Abstract][Full Text] [Related]
5. The epigallocatechin gallate derivative Y
Wen Y; Zhao R; Gupta P; Fan Y; Zhang Y; Huang Z; Li X; Su Y; Liao L; Xie YA; Yang D; Chen ZS; Liang G
Acta Pharm Sin B; 2019 Mar; 9(2):316-323. PubMed ID: 30972279
[TBL] [Abstract][Full Text] [Related]
6. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer.
Liang G; Tang A; Lin X; Li L; Zhang S; Huang Z; Tang H; Li QQ
Int J Oncol; 2010 Jul; 37(1):111-23. PubMed ID: 20514403
[TBL] [Abstract][Full Text] [Related]
7. Reversal of cancer multidrug resistance by green tea polyphenols.
Mei Y; Qian F; Wei D; Liu J
J Pharm Pharmacol; 2004 Oct; 56(10):1307-14. PubMed ID: 15482646
[TBL] [Abstract][Full Text] [Related]
8. Reversal effect of quercetin on multidrug resistance via FZD7/β-catenin pathway in hepatocellular carcinoma cells.
Chen Z; Huang C; Ma T; Jiang L; Tang L; Shi T; Zhang S; Zhang L; Zhu P; Li J; Shen A
Phytomedicine; 2018 Apr; 43():37-45. PubMed ID: 29747752
[TBL] [Abstract][Full Text] [Related]
9. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line.
Farabegoli F; Papi A; Bartolini G; Ostan R; Orlandi M
Phytomedicine; 2010 Apr; 17(5):356-62. PubMed ID: 20149610
[TBL] [Abstract][Full Text] [Related]
10. [MDR-reversing effect of two components of catechin on human hepatocellular carcinoma BEL-7404/Adr in vitro].
Liang G; Zhang S; Huang ZM; Tang AZ
Ai Zheng; 2004 Apr; 23(4):401-5. PubMed ID: 15087027
[TBL] [Abstract][Full Text] [Related]
11. [Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU].
Tang HH; Zhou M; Liang G
Ai Zheng; 2008 Oct; 27(10):1056-64. PubMed ID: 18851785
[TBL] [Abstract][Full Text] [Related]
12. In vivo reversal of doxorubicin resistance by (-)-epigallocatechin gallate in a solid human carcinoma xenograft.
Zhang Q; Wei D; Liu J
Cancer Lett; 2004 May; 208(2):179-86. PubMed ID: 15142676
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of NPM reverses multidrug resistance in human hepatoma cells via inhibition of P-glycoprotein expression.
Luo F; Li H; Liang J; Jia H; Li X; Xiao H; He X; He J; Tian Y; Zhao H
Mol Med Rep; 2017 Apr; 15(4):2360-2368. PubMed ID: 28259962
[TBL] [Abstract][Full Text] [Related]
14. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma.
Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X
Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of epigallocatechin-3-gallate on cell proliferation and the expression of HIF-1α and P-gp in the human pancreatic carcinoma cell line PANC-1.
Zhu Z; Wang Y; Liu Z; Wang F; Zhao Q
Oncol Rep; 2012 May; 27(5):1567-72. PubMed ID: 22367292
[TBL] [Abstract][Full Text] [Related]
16. Modulation of P-glycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells.
Qian F; Wei D; Zhang Q; Yang S
Biomed Pharmacother; 2005 Apr; 59(3):64-9. PubMed ID: 15795098
[TBL] [Abstract][Full Text] [Related]
17. Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells.
Gu W; Liu L; Fang FF; Huang F; Cheng BB; Li B
Oncol Rep; 2014 Jan; 31(1):216-22. PubMed ID: 24173654
[TBL] [Abstract][Full Text] [Related]
18. Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin.
Li H; Krstin S; Wink M
Phytomedicine; 2018 Nov; 50():213-222. PubMed ID: 30466981
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
20. The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance.
Li G; Chen X; Wang Q; Xu Z; Zhang W; Ye L
J Huazhong Univ Sci Technolog Med Sci; 2007 Apr; 27(2):173-5. PubMed ID: 17497289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
